LMed 99
LMed 99 is an antiviral agent. LMed 99 inhibits viral RNA synthesis and reduces viral protein expression in a time-dependent manner. LMed 99 potently inhibits Influenza A virus replication. LMed 99 can be used in the research of Influenza A virus infections (H1N1, H5N1).
For research use only. We do not sell to patients.
- Formula: C18H11ClO5
- Molecular Weight:342.73
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK-II | CC50 |
140.93 μM
|
Cytotoxicity against Canis familiaris distal renal tube epithelial MDCK II cells assessed via MTT assay with 72 h incubation.
Cytotoxicity against Canis familiaris distal renal tube epithelial MDCK II cells assessed via MTT assay with 72 h incubation.
|
42485991 |
| MDCK-II | EC50 |
1.21 μM
|
Inhibition of Influenza A virus H1N1 (strain WSN/33/H1N1) replication in Canis familiaris distal renal tube epithelial MDCK II cells assessed via Focus Forming Assay with 24 h co-incubation of reagent and virus.
Inhibition of Influenza A virus H1N1 (strain WSN/33/H1N1) replication in Canis familiaris distal renal tube epithelial MDCK II cells assessed via Focus Forming Assay with 24 h co-incubation of reagent and virus.
|
42485991 |
| MDCK-II | EC50 |
4.91 μM
|
Inhibition of Influenza A virus H5N1 (strain A/Thailand/KAN-1/2004) replication in Canis familiaris distal renal tube epithelial MDCK II cells assessed via Focus Forming Assay with 24 h co-incubation of reagent and virus.
Inhibition of Influenza A virus H5N1 (strain A/Thailand/KAN-1/2004) replication in Canis familiaris distal renal tube epithelial MDCK II cells assessed via Focus Forming Assay with 24 h co-incubation of reagent and virus.
|
42485991 |
In Vitro
The CC50 of LMed 99 (72 h) in MDCK II cells is 140.93 μM, indicating that it exhibits moderate cytotoxicity at high concentrations[1].
LMed 99 (0.4-350 μM; 24 h) potently inhibits the replication of H1N1 in MDCK II cells, with an EC50 of 1.21 μM and a selectivity index as high as 116.4[1].
LMed 99 (9 μM) significantly reduces H1N1 vRNA accumulation at all tested post-infection time points in MDCK II cells, and inhibits viral mRNA synthesis during the early stages of infection (1 and 3 hpi)[1].
LMed 99 (4.5-9 μM; added 4 h post-transfection and incubated for 20 h) enhances the activity of influenza A virus polymerase-related reporter genes in the MDCK II cell minireplicon system, with a 61.37% increase in activity at 4.5 μM and a 108.97% increase at 9 μM[1].
LMed 99 (1.09-17.5 μM) inhibits the replication of highly pathogenic H5N1 in MDCK II cells, with an EC50 of 4.91 μM and a selectivity index of 28.71, showing favorable performance[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDCK II cells
-
Concentration:9 μM
-
Incubation Time:added at 1 hpi, 3 hpi, or 6 hpi, with incubation until 9 hpi
-
Result:Reduced M1 vRNA levels by 82% (n-fold = 0.18) at 1 and 3 hpi, and by 80% (n-fold = 0.20) at 6 hpi.
Reduced M1 mRNA levels by 78% (n-fold = 0.22) at 1 hpi and 70% (n-fold = 0.30) at 3 hpi, with no significant effect at 6 hpi.
Reduced PB1 mRNA levels by 57% (n-fold = 0.43) at 1 hpi and 22% (n-fold = 0.78) at 3 hpi, with no significant effect at 6 hpi.
Chemical Information
-
Molecular Weight 342.73
-
Formula C18H11ClO5
-
SMILES
ClC1=CC(C=C2C(/C=C/C3=CC=C(C(O)=C3)O)=O)=C(C=C1)OC2=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)